64-Year-Old Male With Metastatic Prostate Cancer, Lung Masses & Liver Lesions — Baseline Status and 4-Week Metabolic Response
BACKGROUND
PET/CT imaging confirmed aggressive, multi-system metastatic disease:
- Multiple lung tumors (SUVmax up to 21.9) — strongly suspicious for second primary lung cancer
- Large liver metastasis (4.8 × 6.2 cm, SUVmax 24.6)
- Additional FDG-avid liver lesions
- Left pleural effusion worsening to 7.4 cm
- Left hilar lymph node metastasis
- Bone metastases (L2–L4) with increased metabolic activity
Despite no local recurrence in the prostate bed, the cancer is clearly progressing systemically.
Baseline PSA: 43.8 ng/mL
BASELINE METABOLIC STATUS (Before protocol)
| Marker | Before | Interpretation |
|---|---|---|
| Fasting Glucose | 107.4 mg/dL | Insulin-resistant state |
| GKI | — | No ketosis → tumors fully glucose-fed |
| AST | 27 | Normal |
| ALT | 19 | Normal |
| GGT | 27 | Normal |
| ALP | 68 | Normal (even with bone metastasis) |
| CEA | 1.48 | Normal |
| CBC | Normal | Strong resilience |
PROTOCOL FOLLOWED
Repurposed Agents
- Fenbendazole
- Ivermectin
- CDS + DMSO
Key Natural Agents
- Curcumin
- Berberine
- Astaxanthin
- Modified Citrus Pectin
- Lactoferrin
- Turkey Tail Mushroom
- Black Seed Oil
- Vitamin D3 + K2
- Apigenin, Lycopene and Saw Palmetto
Metabolic Framework
- Strict ketogenic diet (GKI < 2)
- Intermittent fasting
4-WEEK METABOLIC RESPONSE
| Marker | Before | After | Change |
|---|---|---|---|
| PSA | 43.8 | 28.9 | –34% |
| Fasting Glucose | 107.4 | 97 | Better metabolic control |
| GKI | — | 1.4 | Deep therapeutic ketosis |
| AST | 27 | 16 | Normal |
| ALT | 19 | 15 | Normal |
| GGT | 27 | 28 | Normal |
| ALP | 68 | 70 | Normal |
| CEA | 1.48 | 1.2 | Lower |
| CBC | Normal | Normal | Stable |
INTERPRETATION
This case involves one of the most aggressive cancer patterns:
- Rapid lung progression
- Highly FDG-avid liver metastases
- Pleural carcinomatosis risk
- Bone metastasis
- PSA elevation
- Prior chemo failure
After only 4 weeks of Targeted Metabolic Therapy, the patient demonstrates:
1. PSA reduction of 34%
A strong early sign of reduced systemic cancer activity.
2. Glucose reduction + GKI 1.4
Indicates tight metabolic control and significant pressure on tumor metabolism.
3. Liver enzymes are all normal
Shows safe therapy application despite liver metastatic burden.
4. CBC stable
Indicates excellent tolerance to therapy.
Together, these improvements suggest metabolic stabilization during a phase where conventional oncology expects continued progression.
NEXT STEP
- Continue the full metabolic protocol consistently.
- Maintain GKI <2 for maximum therapeutic pressure.
- Re-check key labs every 4 weeks (PSA, glucose, CEA, liver markers, LDH, CBC, and add CA19.9).
- Repeat PET/CT or MRI in 6 months to evaluate metabolic and structural response.
The direction is correct — the metabolic environment is shifting away from cancer growth and toward control.
